News Johnson & Johnson Buenos Aires S.E.

Equities

JNJ

ARDEUT110236

End-of-day quote Buenos Aires S.E. Other stock markets 18:00:00 2024-05-28 EDT			5-day change	1st Jan Change
11,691 ^ARS	-1.82%		-8.88%	+15.36%

10:58am	Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400	MT
05-29	Transcript : Johnson & Johnson Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 01:30 PM

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400	04:58am	MT
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Press Release	05-29	PU
Transcript : Johnson & Johnson Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 01:30 PM	05-29
J&J: encouraging results in the treatment of depression	05-29	CF
Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints	05-29	MT
J&J's treatment for depression succeeds in late stage study	05-29	RE
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	05-29	AQ
Sector Update: Health Care Stocks Fall Late Afternoon	05-28	MT
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	05-28	MT
Sector Update: Health Care	05-28	MT
Bio-Thera, Stada Enter Deal for Biosimilar Candidate to Johnson & Johnson's Simponi in EU, UK	05-28	MT
Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion	05-28	MT
Top Midday Stories: Wall Street Returns to T+1 Settlements; T-Mobile Buys US Cellular's Wireless Ops; Energy Transfer Buys WTG Midstream; GameStop Extends Rally	05-28	MT
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	05-28	MT
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	05-28	MT
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion	05-28	MT
J&J: acquisition of Swiss eczema biotech company	05-28	CF
J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal	05-28	DJ
J&J acquires rights to skin disorder drug for $1.25 bln	05-28	RE
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	05-28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm